miR-506, miR-103 and miR-107 are robust clinical markers for the chemotherapy response and survival in patients with ovarian cancer and can sensitize cancer cells to DNA damage by directly targeting RAD51 and inhibiting the formation of RAD51 foci [49, 50]. This evidence concerns the gene RAD51 and ovarian carcinoma.